Metraipolis › archive › dc_c6dfd5a60ece

Development and characterization of a recombinant Bundibugyo virus expressing a fluorescent reporter protein — Europe PMC PMID:42496613

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42496613
DOI: 10.1080/22221751.2026.2709847
License (as archived): CC0-1.0
Archived: 2026-10-06T07:55:37.957Z
SHA-256 of the archived text: 740f882bdb6cf389849cda20efc5865db0bf1b6d3db7927f026b77b0d45859ea
Stable URL of this page: https://metraipolis.com/documento/dc_c6dfd5a60ece

How to cite

Development and characterization of a recombinant Bundibugyo virus expressing a fluorescent reporter protein — Europe PMC PMID:42496613 — Europe PMC (en), https://europepmc.org/article/MED/42496613 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_c6dfd5a60ece (Metraipolis archive dc_c6dfd5a60ece, sha256 740f882bdb6cf389849cda20efc5865db0bf1b6d3db7927f026b77b0d45859ea)

BibTeX

@misc{dcc6dfd5a60ece,
  title = {Development and characterization of a recombinant Bundibugyo virus expressing a fluorescent reporter protein — Europe PMC PMID:42496613},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42496613},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_c6dfd5a60ece; sha256 740f882bdb6cf389849cda20efc5865db0bf1b6d3db7927f026b77b0d45859ea},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/42496613. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Bundibugyo virus disease (BVD), caused by Bundibugyo virus (BDBV), is associated with substantial morbidity and mortality, with previous outbreaks reporting case fatality rates of 30%-50%. The ongoing BDBV outbreak in the Democratic Republic of the Congo and Uganda highlights the urgent need for virus-specific research tools and medical countermeasures. Unlike Ebola virus disease caused by Zaire ebolavirus, no licensed vaccines or specific therapeutics are currently available for BVD. The lack of research tools has limited studies with BDBV. To facilitate antiviral testing and neutralization studies, we developed the first recombinant BDBV expressing the fluorescent reporter protein ZsGreen (rBDBV-ZsG). As a proof of concept, we tested a set of previously characterized antiviral compounds and demonstrated comparable inhibitory profiles between rBDBV-ZsG and the wild-type BDBV parental strain. Furthermore, the utility of rBDBV-ZsG was successfully evaluated in neutralization assays, demonstrating robust sensitivity and specificity using monoclonal antibodies and convalescent serum samples.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: Emerging microbes & infections, 2026 (prima pubblicazione 2026-08-03).
Identificativi: PMID 42496613 · PMCID PMC13435268 · DOI 10.1080/22221751.2026.2709847.
Parole chiave degli autori: Neutralization; outbreak; Antivirals; Ebola Virus; Bdbv; Bundibugyo Virus.
Descrittori MeSH principali: Filoviridae; Bunyaviridae Infections; Luminescent Proteins.
Pagina: https://europepmc.org/article/MED/42496613 — https://doi.org/10.1080/22221751.2026.2709847. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T07:47:50.168Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.